key: cord-0775545-3437crq4
authors: Pochon, Cécile; Notarantonio, Anne‐Béatrice; Laroye, Caroline; Reppel, Loic; Bensoussan, Danièle; Bertrand, Allan; Rubio, Marie‐Thérèse; D’Aveni, Maud
title: Wharton’s jelly‐derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation
date: 2022-01-28
journal: J Cell Mol Med
DOI: 10.1111/jcmm.17105
sha: 531eb1d35bc5ac768b45db77099b0830d8cc1bf8
doc_id: 775545
cord_uid: 3437crq4

For decades, mesenchymal stromal cells (MSCs) have been of great interest in the fields of regenerative medicine, tissue engineering and immunomodulation. Their tremendous potential makes it desirable to cryopreserve and bank MSCs to increase their accessibility and availability. Postnatally derived MSCs seem to be of particular interest because they are harvested after delivery without ethical controversy, they have the capacity to expand at a higher rate than adult‐derived MSCs, in which expansion decreases with ageing, and they have demonstrated immunological and haematological supportive properties similar to those of adult‐derived MSCs. In this review, we focus on MSCs obtained from Wharton's jelly (the mucous connective tissue of the umbilical cord between the amniotic epithelium and the umbilical vessels). Wharton's jelly MSCs (WJ‐MSCs) are a good candidate for cellular therapy in haematology, with accumulating data supporting their potential to sustain haematopoietic stem cell engraftment and to modulate alloreactivity such as Graft Versus Host Disease (GVHD). We first present an overview of their in‐vitro properties and the results of preclinical murine models confirming the suitability of WJ‐MSCs for cellular therapy in haematology. Next, we focus on clinical trials and discuss tolerance, efficacy and infusion protocols reported in haematology for GVHD and engraftment.

MSCs have been isolated from multiple adult tissues other than bone marrow, including skeletal muscle, adipose tissue, synovial membranes, saphenous veins, dental pulp, periodontal ligaments, lung, liver and skin. MSCs obtained from extra-embryonic tissues (such as placenta/umbilical cord, Wharton's jelly and amniotic membrane) share properties with their adult counterparts. They also retain characteristics of primitive stem cells, like the expression of the embryonic stem cell markers Oct-4, Nanog, Sox-2 and c-Kit, as well as Dnmt3b and hTERT, albeit at much lower levels than those of embryonic stem cells. 5 They have many advantages for cellular therapy applications: available after delivery, their collection and expansion raise no ethical issues. They usually expand with a higher proliferation rate 6 and a broader multipotency than MSCs from adult tissues, though donor age affects these characteristics in bone marrowderived MSCs (BM-MSCs). 7 Wharton's jelly mesenchymal stromal cells (WJ-MSCs), were first isolated in 1991. 8 Their immunomodulatory properties and their low cellular immunogenicity 9 make them remarkably interesting for the induction of tolerance in transplantation. A few in vitro studies have reported that WJ-MSCs are less immunogenic than MSCs from other sources, especially when cultivated in hypoxia. 10 Amongst MSCs, WJ-MSCs have the lowest level of MHC class II expression. Moreover, they express low levels of cellsurface MHC class I and costimulatory molecules (CD40, CD80, CD86). In a comparative study of foetal adnexa-derived caprine MSCs, WJ-MCs outperformed MSCs from other sources of foetal adnexa (amniotic fluid, amniotic sac, cord blood) in terms of growth kinetics, relative messenger ribonucleic acid (mRNA) expression of surface antigens, pluripotency markers, and tri-lineage differentiation potential. 11 In allogeneic haematopoietic stem cell transplantation (allo-HSCT), BM-MSCs were the first described cells of potential interest. They have been mainly (and widely) studied in the treatment of steroid-refractory graft versus host disease (GVHD), with results varying depending on the study and the methods used. [12] [13] [14] Another topic of research has been their haematopoietic support functions since they are key players in the haematopoietic niche and can enhance haematopoietic stem cell (HSC) engraftment and function. [15] [16] [17] However, in this area of research, their efficacy remains to be established. 15, 18 Several studies, which we describe below, have compared MSCs isolated from the most common sources in terms of their functional differences in immune modulation and haematopoietic support.

MSCs derived from amnion, placenta, Wharton's jelly and umbilical cord blood elicit a similar degree of immunosuppression in vitro compared with that of BM-MSCs, but Manochantr et al. have demonstrated that WJ-MSCs have a higher proliferative capacity. 19 MSCs derived from WJ and adipose tissue have potent immunosuppressive effects on T cells, similar 20 or even superior to that observed with BM-MSCs. 21 WJ-MSCs have a capacity to suppress neutrophil adhesion to inflamed endothelium similar to that of BM-MSCs, but conserve their immune-suppressive properties after passage 7, unlike BM-MSCs. 22 In a murine model of experimental sepsis, mice treated with WJ-MSCs had a higher survival rate than mice treated with BM-MSCs. 23 In another study, by Karaöz et al, WJ-MSC co-culture with activated T cells led to a higher concentration of IL-17A, which would be of particular interest in a GVHD context. 24 In a recent work, Shin et al. analysed the protein secretome of four sources of MSCs: adipose tissue, bone marrow, placenta, and WJ. Each MSC secretome profile had distinct characteristics, depending on the source. The secretome of foetal-derived MSCs (placenta and WJ) had a more diverse composition than those of adipose tissue and BM-MSCs, and the authors assumed that their therapeutic potential was greater because of these properties. 25

One study found more proteins related to tissue development and the differentiation of haematopoietic cells in the secretome of WJ-MSCs compared with adipose tissue and BM-MSCs. 25 Moreover, CD117 (c-kit) the receptor for stem cell factor (SCF) harboured by haematopoietic stem/progenitor cells (HSPCs), has been repeatedly detected in WJ-MSCs. 26 WJ-MSCs express osteopontin and are able to secrete hyaluronic acid. 27 Interestingly, both these molecules are amongst the main constituents of the HSPC niche. Osteopontin is a critical regulator of HSPC localization and proliferation. 27, 28 Human WJ-MSCs have been compared with BM-MSCs and show similar haematopoiesis-supportive functions in vitro, when co-cultured with CD34 + umbilical cord blood cells. 29 In a murine model, cotransplantation of either WJ-MSCs or BM-MSCs with CD34 + HSCPs from cord blood resulted in similarly enhanced recoveries of human platelets and CD45 + cells in the peripheral blood and a 3-fold higher engraftment in the bone marrow, blood, and spleen 6 weeks after transplantation when compared with transplantation of CD34 + cells alone. 30 Considering their low immunogenicity, their immunomodulatory and haematopoietic supportive properties in vitro, their growth kinetics, and their proteome diversity, WJ-MSCs are remarkably interesting cells for potential use in GVHD and haematopoietic engraftment ( Figure 1 ).

In the setting of sustaining haematopoiesis, MSCs from placenta and umbilical cord display interesting properties in vitro. 30 They promote growth and preserve the stemness of haematopoietic stem cells (HSCs) from autologous or allogeneic cord blood in twodimensional cultures, 31, 32 and in three-dimensional scaffolds. 33 WJ-MSCs have been recently exploited as a feeder layer to expand haematopoietic stem cells, providing secreted proteins 34 and cytokines involved in the regulation of haematopoiesis, including interleukin (IL)-6, SCF, Fms-like tyrosine kinase 3-ligand (Flt-3L), macrophage colony-stimulating factor, granulocyte colonystimulating factor and granulocyte-monocyte colony-stimulating factor (Table 1) . 35 

Studies in NOD/SCID/IL2Rγnull (NSG) mice suggest that WJ-MSCs may increase haematologic recovery. 36 Six weeks after allogeneic stem cell transplantation, NSG mice co-transplanted with 1 × 10 6 WJ-MSCs demonstrated a significantly higher median number of human CD45 + cells engrafting in the peripheral blood and bone marrow than those transplanted without WJ-MSCs: respectively, 28.2% (range, 24.6-33.1%) versus 5.3% (range, 4.2-6.5%) and 6 .9% (range, 5.9-7.3%) versus 1.7% (range, 1.5-2.3%). WJ-MSCs were obtained from umbilical cords as follows: the main vessels were removed and the jelly was digested using 1 mg/ml collagenase. Cell culture was normoxic, and cells were cryopreserved before use. WJ-MSCs were selected if they matched at least three HLA alleles with recipients, then expanded and cryopreserved a F I G U R E 1 WJ-MSCs support haematopoiesis and modulate immunity via soluble factors and cell-cell contact. Upper: WJ-MSCs secrete growth factors that may enhance haematopoietic cell renewal or stemness, and they may create a fibronectin network that supports haematopoietic cell homeostasis. Thus, they are of interest in the treatment of poor graft function after HSCT. IL-6: Interleukin-6, SCF: stemcell factor, M-CSF: macrophage colony-stimulating factor, G-CSF: granulocyte colony-stimulating factor, GM-CSF: granulocyte macrophage colony-stimulating factor, Flt3: Fms-like tyrosine kinase 3; Lower: WJ-MSCs secrete cytokines and other molecules that decrease activated T-cell proliferation, or induce Tregs, and act on other immune cells. They also produce cytosolic IDO, an enzyme that depletes tryptophan in the medium and converts tryptophan into secreted metabolites (like kynurenine) that prevent T-cell proliferation. WJ-MSCs also express several membrane molecules that interact with activated T cells to induce exhaustion or apoptosis, or to prevent T-cell activation. The expression of soluble and membrane factors varies according to the level of inflammation in the environment. These properties make WJ-MSCs good candidates for GVHD prophylaxis or cure, for graft rejection prophylaxis, and for some disorders of uncontrolled inflammation, such as haemorrhagic cystitis. PGE2, prostaglandin E2; HGF, hepatic growth factor; IL, interleukin; TGF β1, transforming growth factor β1; HLA, human leukocyte antigen; PDL (1/2), programmed-death ligand; VCAM, vascular cell adhesion molecule; ICAM, intercellular adhesion molecule second time. They were infused into patients immediately after thawing, at an average dose of 1.2 × 10 6 / kg (range, 0.27-2.5 × 10 6 / kg). None of the patients experienced graft rejection, and all had rapid engraftment (mean times for neutrophil and platelet recovery were 13.95 days and 20.27 days, respectively). No severe acute GVHD (aGVHD) and no chronic GVHD (cGVHD) were observed.

With a median follow-up of 15 months, 21 patients were alive and transfusion-independent with full donor chimerism. This report has been confirmed in 17 SAA adult patients treated with haploidentical HSCT after a reduced-intensity conditioning regimen and with co-infusion of culture-expanded third-party donor-derived WJ-MSCs 4 hours before allo-HSCT. 38 In this study, WJ-MSCs were obtained after the cord was sectioned, without enzymatic digestion.

Cells were thawed only once, in autologous plasma from cord blood, and re-expanded before their use at day 0 of HSC transplantation.

Moreover, 17 children and adolescents with SAA were treated with haploidentical HSCT after myeloablative conditioning and coinfusion of culture-expanded third-party donor-derived WJ-MSCs 

The first phase 1 trial published with WJ-MSC administration in the treatment of acute GVHD was performed in the USA. WJ-MSCs were used immediately after thawing but the culture conditions were not described. Ten patients with de novo high risk or steroid-refractory acute GVHD received WJ-MSCs intravenously on days 0 and 7 (low-dose cohort, 2 × 10 6 /kg, n = 5; high-dose cohort, 10 × 10 6 /kg, n = 5). No infusion-related toxicity, treatmentrelated adverse events, or ectopic tissue formation was observed in either cohort. Clinical response was suggested at day 28, as the overall response rate (ORR) was 70%, with a complete response in 

In 

Only a few studies have sought to determine the impact of WJ-MSC co-injection on immune reconstitution during the few months following allo-HSCT. 53 In a controlled, randomized multicentre study, four monthly injections of 3 × 10 7 WJ-MSCs after haploidentical HSCT for chronic GVHD prevention led to a decrease in total NK cells.

Although the numbers of CD3 + CD4 + cells did not differ significantly between the two groups, the number of CD4 + CD25 + CD127 low regulatory T (Treg) cells in the MSC group was higher than that in the non-MSC group. And although the numbers of CD19 + B cells were not significantly different, the CD27 + memory B-lymphocyte numbers were significantly increased after MSC infusion. Moreover, during the first month post HSCT, the Th1 (interferon γ): Th2 interleukin (IL)-4 + cell ratio increased. 53 Another study of WJ-MSC injections in 24 patients with refractory GVHD treatment showed that patients had lower levels of mature dendritic cells (CD83 + , CD86 + , and HLA-DR + cells) after MSC infusion (between days +14 and days +56) than before MSC infusion 54 (Table 1) .

In this review we have presented the reasons why WJ-MSCs are attracting interest in haematology (summarized in Table 1 ). They have Figure 1 ), since they may undergo polarization to either MSC1s or

MSC2s according to the environment. 68 EVs do not have this plasticity, and the priming of WJ-MSCs with inflammatory cytokines should be considered before exosome collection in the field of GVHD. 69 Second, WJ-MSC phagocytosis by monocytes in vivo has been described as a key mechanism of immunomodulation, 45, 59 and nothing is known about that phenomenon in regard to MSC-derived EVs.

Third, cell preparation is an important variable that must be better defined before WJ-MSC use in human therapy. For instance, since WJ-MSCs are banked, the impact of freezing and thawing these cells before use must be carefully studied. Some authors have noted that BM-MSCs need a few days of culture after thawing to recover their full immunological properties. [70] [71] [72] [73] This was not confirmed in a preclinical pig model of septic shock where thawed human WJ-MSCs were immediately infused and provided significant clinical and biological improvements. 74 The culture medium 75 and culture atmospheric conditions are also correlated with WJ-MSC functions. 19 Hypoxia has been described as a favourable condition in maintaining HSC stemness, 76 but its impact on WJ-MSC immune properties is not well characterized to date. The only published means of enhancing their immune capacities is to licence WJ-MSCs with pro-inflammatory cytokines , 77 for instance IFNγ, which improves their function in preventing GVHD in mouse models. 49, 78 In the haematopoietic support setting as well, the cell preparation protocol appears to be of great importance to full WJ-MSC potency. Threedimensional culture of MSCs with HSCs enhances the expansion of cord blood CD34 + cells. 79 Ex vivo expansion of HSCs without eliminating the long-term repopulating capacity of more primitive HSCs is more feasible when haematopoietic niches are mimicked. 80 In this niche, cell contact between WJ-MSCs and HSCs seems to be preferable. 34 The surface structure of the microenvironment has also been shown to modify the cytokine secretion profile of MSCs. 81 Even the stiffness of polydimethylsiloxane substrates for BM-MSC culture can lead to a change in HSPC phenotype. 82 in Belgium, NCT02032446 in Italy, NCT03847844 in Malaysia and NCT04738981 and NCT04213248 in China).

Not applicable.

The authors declare that they have no competing interests. 

Not applicable.

Cécile Pochon https://orcid.org/0000-0003-0277-5611

Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo

Multilineage potential of adult human mesenchymal stem cells

Mesenchymal stem cells reside in virtually all post-natal organs and tissues

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for cellular therapy position statement

Comparative growth behaviour and characterization of stem cells from human Wharton's jelly

Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue

Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells

Isolation, culture and characterisation of fibroblast-like cells derived from the Wharton's jelly portion of human umbilical cord

Immune properties of human umbilical cord Wharton's jelly-derived cells

Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells

A Comparative study of growth kinetics, in vitro differentiation potential and molecular characterization of fetal adnexa derived caprine mesenchymal stem cells

Singlearm, prospective study of remestemcel-l, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease

A phase 3 randomized study of remestemcel-l versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease

Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation "MSC-FFM"-outcome report of 92 patients

Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation?

Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study

Cotransplantation of HLAidentical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients

Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?-a systematic review and meta-analysis

Immunosuppressive properties of mesenchymal stromal cells derived from amnion, placenta, Wharton's jelly and umbilical cord

Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources

Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor

Comparative ability of mesenchymal stromal cells from different tissues to limit neutrophil recruitment to inflamed endothelium

Bone marrow vs Wharton's jelly mesenchymal stem cells in experimental sepsis: a comparative study

Comparative analyses of immunosuppressive characteristics of bone-marrow, wharton's jelly, and adipose tissue-derived human mesenchymal stem cells

Comparative proteomic analysis of the mesenchymal stem cells secretome from adipose, bone marrow, placenta and Wharton's Jelly

New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity

Wharton's jelly mesenchymal stromal cells as a feeder layer for the ex vivo expansion of hematopoietic stem and progenitor cells: a review

Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells

Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesissupportive function and other potentials

Direct comparison of Wharton's Jelly and bone marrow-derived mesenchymal stromal cells to enhance engraftment of cord blood CD34(+) transplants

Human mesenchymal stem/stromal cells from umbilical cord blood and placenta exhibit similar capacities to promote expansion of hematopoietic progenitor cells in vitro

Allogeneic human umbilical cord Wharton's jelly stem cells increase several-fold the expansion of human cord blood CD34+ cells both in vitro and in vivo

Umbilical cord blood mesenchymal stem cells application in hematopoietic stem cells expansion on nanofiber three-dimensional scaffold

Wharton's Jelly mesenchymal stromal cells support the expansion of cord blood-derived CD34+ cells mimicking a hematopoietic niche in a direct cell-cell contact culture system

Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation

Human application of ex vivo expanded umbilical cord-derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation

Hematopoietic stem cell transplantation with umbilical cord multipotent stromal cell infusion for the treatment of aplastic anemia-a single-center experience

Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia

Good outcome of haploidentical hematopoietic SCT as a salvage therapy in children and adolescents with acquired severe aplastic anemia

Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD

Immunosuppressive properties of Wharton's jelly-derived mesenchymal stromal cells in vitro

Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graftversus-host disease

Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells

Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly

Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells

Hypoxic culture conditions for Mesenchymal Stromal/Stem Cells from Wharton's jelly: a critical parameter to consider in a therapeutic context

Umbilical cordderived mesenchymal stromal cells: predictive obstetric factors for cell proliferation and chondrogenic differentiation

Optimization of the therapeutic efficacy of human umbilical cord blood-mesenchymal stromal cells in an NSG mouse xenograft model of graft-versus-host disease

Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-γ. EBioMedicine

A phase i study to evaluate two doses of wharton's jelly-derived mesenchymal stromal cells for the treatment of de novo high-risk or steroid-refractory acute graft versus host disease

Haploidentical hematopoietic stem cell transplant with umbilical cord-derived multipotent mesenchymal cell infusion for the treatment of high-risk acute leukemia in children

Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells with a myeloablative regimen for refractory/relapsed hematologic malignancy

Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stemcell transplantation

Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations

Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?

The homing of human umbilical cord-derived mesenchymal stem cells and the subsequent modulation of macrophage polarization in type 2 diabetic mice

Radiolabeling of umbilical cord-derived mesenchymal stem cells for in vivo tracking

Intravenous human umbilical cord-derived mesenchymal stromal cell administration in models of moderate and severe intracerebral hemorrhage

Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation

Mesenchymal stem cellderived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases

Mesenchymal stromal cell-derived extracellular vesicles promote myeloid-biased multipotent hematopoietic progenitor expansion via toll-like receptor engagement

Mesenchymal stromal cell-derived extracellular vesicles as cell-free biologics for the ex vivo expansion of hematopoietic stem cells

Mesenchymal stromal cell derived extracellular vesicles rescue radiation damage to murine marrow hematopoietic cells

Extracellular vesicles from Wharton's jelly mesenchymal stem cells suppress CD4 expressing t cells through transforming growth factor beta and adenosine signaling in a canine model

Exosomes derived from human umbilical cord mesenchymal stem cells relieve inflammatory bowel disease in mice

Extracellular vesicles released from human umbilical cord-derived mesenchymal stromal cells prevent life-threatening acute graft-versus-host disease in a mouse model of allogeneic hematopoietic stem cell transplantation

WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1

A new Mesenchymal Stem Cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype

Exosomes originating from MSCs stimulated with TGF-β and IFN-γ promote Treg differentiation

The utilization of freezing steps in Mesenchymal Stromal Cell (MSC) Manufacturing: potential impact on quality and cell functionality attributes

Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing

Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?

Cryopreserved mesenchymal stromal cells are susceptible to T-cell mediated apoptosis which is partly rescued by IFNγ licensing

Clinical-grade mesenchymal stem cells derived from umbilical cord improve septic shock in pigs

Manufacturing of human Wharton's jelly stem cells for clinical use: selection of serum is important

Hypoxia with Wharton's jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34+ cells

Functional enhancement strategies for immunomodulation of mesenchymal stem cells and their therapeutic application

IFN-γ gene loaded human umbilical mesenchymal stromal cells targeting therapy for Graft-versus-host disease

Co-culture of umbilical cord blood CD34+ cells with human mesenchymal stem cells

Hematopoietic Niche -Exploring Biomimetic Cues to Improve the Functionality of Hematopoietic Stem/Progenitor Cells

The cytokine secretion profile of mesenchymal stromal cells is determined by surface structure of the microenvironment

Improving hematopoietic recovery through modeling and modulation of the mesenchymal stromal cell secretome

IL-1β promotes the hematopoietic support of human umbilical cord mesenchymal stem cells

Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment

Donor-dependent variation of human umbilical cord blood mesenchymal stem cells in response to hypoxic preconditioning and amelioration of limb ischemia

How to cite this article

Wharton's jelly-derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation